Peptide Encyclopedia / PT-141
EncyclopediaPT-141 is a melanocortin-receptor agonist that works in the brain on sexual-desire pathways rather than through blood flow. The FDA approved it in 2019 as Vyleesi for acquired HSDD in premenopausal women, with no approval for men, erectile dysfunction, or performance. Educational only, not medical advice.
| Category | Sexual Health |
| Half-life | 2 |
| Regulatory status | FDA-approved only as Vyleesi (bremelanotide) for premenopausal HSDD; PT-141 sold as a research chemical is unapproved. |
A melanocortin-receptor agonist that acts centrally in the brain to influence sexual-desire pathways (not via vascular/blood-flow effects).
~2.7 hours (terminal half-life from clinical data); relatively well established.
FDA-approved. Marketed as Vyleesi (bremelanotide) since 2019 for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. NOT approved for men, for erectile dysfunction, or to enhance performance. Compounded versions for other uses are unapproved.
Nausea (common), flushing, injection-site reactions, headache; can transiently raise blood pressure and lower heart rate (caution in CV disease); focal hyperpigmentation with repeated use. Contraindicated in uncontrolled hypertension / known CV disease.
Multiple human clinical trials (RECONNECT Phase 3 program).
Log every dose and injection site, get the reconstitution and units math automatically, follow your cycle, and record how you feel, then export a provider report. PT-141 tracker, free to start.
PepWise is an informational and educational tracking tool, not medical advice and not a medical device. PT-141 may be experimental, restricted, or prescription-only; many research peptides are not FDA-approved. Consult a licensed healthcare provider before starting, changing, or stopping any protocol. Operated by STC Consulting, Inc.
